• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Primary Osteoarthritis Companies

    ID: MRFR/Pharma/3937-HCR
    120 Pages
    Rahul Gotadki
    October 2025

    Primary osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage in the joints. Companies involved in primary osteoarthritis may focus on the development of pharmaceuticals, medical devices, and treatments aimed at managing the symptoms and progression of this condition.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Primary Osteoarthritis Market Research Report - Global Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Primary Osteoarthritis Market

    Primary Osteoarthritis Key CompaniesLatest Primary Osteoarthritis Companies Update

    Sep 2023: Government documents reveal that the state of Goa in India has notified Abbott Laboratories' local business (ABT.N) that it intends to revoke the license to manufacture its antacid medication after inspectors discovered contamination concerns and sanitization problems at the factory. The American pharmaceutical business is embroiled in a battle with drug inspectors in the western Indian state of Goa, a popular vacation destination. The company voluntarily recalled numerous batches of Digene Gel syrup made in Goa beginning in August after receiving customer complaints regarding its taste and odor. The health of the patient is unaffected, according to Abbott. Healthcare data indicates that Digene holds a 7% market share for so-called antiflatulent drugs in India, where Abbott operates two factories: Goa and Hyderabad.


    Nov 2023: The US Food and Drug Administration (FDA) has approved Astellas Pharma Inc. and Pfizer Inc.'s supplementary New Drug Application for the small-molecule medication Xtandi (enzalutamide). The companies made this announcement. Based on the findings of the phase 3 Embark trial, the FDA expedited development and review processes. With this approval, Xtandi becomes the first and sole androgen receptor signaling inhibitor authorized by the FDA for the treatment of individuals with biochemically driven recurrence of high-risk prostate cancer (high-risk BCR) who have nonmetastatic castration-sensitive prostate cancer (nmCSPC). Xtandi may be used in combination with gonadotropin-releasing hormone (GnRH) analog treatment for patients with nmCSPC and high-risk BCR.List of Primary Osteoarthritis Key companies in the market

    • Abbott Laboratories (U.S.)

    • Johnson & Johnson Limited (U.S.)

    • Novartis AG (Switerzland)

    • Pfizer, Inc. (U.S.)

    • Eli Lilly and Company (U.S.)

    • Abiogen Pharma (Italy) 

    • Ampio pharmaceuticals (U.S.) 

    • BioDelivery Sciences International (U.S.)

    • CrystalGenomics (South Korea)

    • Daiichi Sankyo (Japan)

    • Eli Lilly (U.S.)

    • Horizon Pharma (Republic of Ireland)

    • Iroko Pharmaceuticals (U.S.)

    • Merck & Co. Ltd (U.S.)

    • Nuvo Research (U.S.)

    • Regeneus (Australia)

    • Sanofi (France)

    • SantoSolve (U.S.) 

    • Smith & Nephew (UK)

    • Winston Pharmaceuticals (India).